Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
Cartherics and Catalent Expand Commercial License Agreement
08:00am, Thursday, 09'th Apr 2026
MELBOURNE, Australia & TAMPA, Fla.--(BUSINESS WIRE)--Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women's diseases, including ovaria
TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent and GelMEDIX Enter Global Partnership for manufacturing and development of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases.
SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs
07:00am, Monday, 12'th Jan 2026
TULLINGE, Sweden & TAMPA, Fla.--(BUSINESS WIRE)--SmartCella and Catalent have entered a nonexclusive license agreement for induced pluripotent stem cells (iPSCs) for developing regenerative therapies.
BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative thera
Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”
12:01am, Tuesday, 28'th Oct 2025
TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscor
Lisata Therapeutics CEO discusses Catalent deal - ICYMI
04:06pm, Saturday, 11'th Oct 2025
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company's new collaboration with Catalent, which reinforces its strategy to leverage the broad applicability of
Lisata Therapeutics CEO discusses Catalent deal - ICYMI
11:53am, Saturday, 11'th Oct 2025
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company’s new collaboration with Catalent, which reinforces its...
Lisata Therapeutics inks global product license deal with Catalent
09:59am, Wednesday, 08'th Oct 2025
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a global product license agreement with Catalent Inc, which would allow Catalent to incorporate Lisata's certepetide into
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
11:32am, Tuesday, 23'rd Sep 2025
The U.S. Food and Drug Administration (FDA) on Tuesday issued a Complete Response Letter (CRL) for Scholar Rock's SRRK apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA)
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug
10:02am, Tuesday, 23'rd Sep 2025
Shares of Scholar Rock tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug, citing concerns at a plant.
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
08:00am, Thursday, 04'th Sep 2025
Science 37 and Catalent announce a strategic partnership enabling direct-to-patient investigational medicinal product (IMP) delivery for clinical research.
Key industry drivers include cost advantages in China, 100% FDI in India, and demand for injectable drugs in cancer research Key industry drivers include cost advantages in China, 100% FDI in India, a
Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors
08:00am, Thursday, 15'th May 2025
EMERYVILLE, Calif.--(BUSINESS WIRE)--Prolific Machines announces appointment of Julien Meissonnier, former Chief Scientific Officer of Catalent, to its Board as an Independent Director.
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI
10:56am, Saturday, 19'th Apr 2025
Lisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration with Catalent. The company told investors tha
Lisata Therapeutics signs research license with Catalent
09:17am, Tuesday, 15'th Apr 2025
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its iRGD cyclic peptide candidate, using Catalent's SMARTag
